Project Grant R01AA031760
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) awarded a Project Grant of $140,340 to The Regents of the University of Colorado–Denver, with performance from December 1, 2025, through June 30, 2028. The research project investigates the role of the C5 complosome in ethanol-induced immunometabolic dysregulation of Kupffer cells in alcohol-associated liver disease (ALD). Specifically, the research will...
- Federal Project Grant Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded $249,000 to Indiana University Indianapolis on September 12, 2025, under the Alcohol Research Programs (CFDA 93.273) to support a three-year research project concluding August 31, 2028. The award funds mechanistic research investigating the role of neutrophilic NCF1 (p47phox) in alcohol-associated liver disease (ALD) pathogenesis. The research addresses a critical gap in understanding how...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $596,476 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), effective May 1, 2026, with completion targeted for February 28, 2031. The project investigates the role of acute phase response (APR) signaling in alcohol-associated liver disease (ALD) resolution following alcohol cessation. The research aims...
- Federal Grant Award Summary Yale University received a $440,566 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 16, 2025, with a completion date of August 31, 2027. The grant funds research to advance treatment of alcohol-associated liver disease (ALD) through precision targeting of methyltransferase-like (METTL) protein family members, specifically METTL7A. The project will deliver mechanistic...
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) under its Alcohol Research Programs (CFDA 93.273) awarded a $498,000 Project Grant to The Trustees of Columbia University in the City of New York on September 25, 2025, with completion targeted for August 31, 2028. This mentored research initiative will develop innovative methodologies to measure stigma associated with women's alcohol use across the lifespan and examine the intergenerational transmission...
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a $161,000 Project Grant under the Alcohol Research Programs (CFDA 93.273) effective September 15, 2025, with a completion date of August 31, 2027. This grant funds mechanistic research investigating the metabolic basis of sarcopenia (skeletal muscle loss) in alcohol-related liver disease (ALD). The research employs...
- Federal Grant Award Summary The University of Arizona received a $1,280,415 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to investigate the role of hepatocyte Forkhead Box A3 (FOXA3) in the development and progression of alcohol-associated liver disease (ALD). The award, issued September 12, 2025, with a completion date of June 30, 2030, supports research that will employ gain-and-loss-of-function approaches...
- Federal Grant Award Summary Yale University received a $659,865 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded on September 16, 2025, with a completion date of July 31, 2030. The grant funds research examining the role of inositol trisphosphate receptor 3 (ITPR3) and aberrant mitochondrial calcium signaling in the pathophysiology of alcohol-associated hepatitis (AAH). The project addresses a critical...
- Federal Project Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded $613,750 to The Regents of the University of California, San Francisco on June 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to fund research investigating the relationship between brain glucose metabolism and alcohol use disorder (AUD). The project, scheduled for completion by April 30, 2031, focuses on elucidating molecular mechanisms by which alcohol alters glycolysis—the...
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $413,496 Project Grant to The Research Foundation for the State University of New York on September 20, 2025, to support research under the Alcohol Research Programs (CFDA 93.273). The project, titled "Enhancing Alcohol Use Disorder Recovery by Capturing the Dynamics of Psychological Well-Being in Daily Life," will operate through August 31, 2027, and will be conducted at the...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $2,359,200 under the Alcohol Research Programs (CFDA 93.273) with an award date of July 15, 2026, and completion targeted for June 30, 2030. This research initiative focuses on elucidating the regulation of hepatocyte functions by hepatic stellate cells (HSCs) in the context of steatotic liver diseases (SLD), including alcohol-associated liver disease (ALD), metabolic dysfunction-associated fatty liver disease (MASLD), and mixed forms (METALD). The project aims to characterize a novel R-spondin 3 (RSPO3)-mediated mesenchymal-epithelial crosstalk mechanism through which HSCs regulate beta-catenin activity in hepatocytes, thereby controlling critical metabolic pathways including bile acid, lipid, and amino acid metabolism. The research will generate fundamental scientific knowledge regarding protective HSC functions in hepatic homeostasis, aging, and disease progression across various forms of SLD. Through experimental characterization of the RSPO3-HSC-hepatocyte axis, the project is expected to advance understanding of shared pathophysiological mechanisms underlying alcohol-related and metabolic liver diseases, potentially informing development of improved therapeutic strategies and prevention approaches for conditions affecting approximately 40 percent of the adult population both domestically and globally.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.4m | 7/17/26 |